T cells genetically targeted with a chimeric antigen receptor (CAR) to B-cell malignancies
have demonstrated tremendous clinical outcomes. With the proof in principle for CAR T cells …

Second-generation chimeric antigen receptors (CARs) are powerful tools to redirect antigen-
specific T cells independently of HLA-restriction. Recent clinical studies evaluating CD19 …

Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis.
Only those patients able to achieve a second remission with no minimal residual disease …

Immunotherapy has demonstrated significant potential for the treatment of patients with
chemotherapy-resistant hematologic malignancies and solid tumors. One type of …

We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-
ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen …

We report the findings from the first 10 patients with chemotherapy-refractory chronic
lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have …

Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …

Activated T cells differentiate into functional subsets with distinct metabolic programs.
Glutaminase (GLS) converts glutamine to glutamate to support the tricarboxylic acid cycle …

Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …

CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-
cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable …